|
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Glial Fibrillary Acidic Protein (GFAP), Plasma
Test Code14319
CPT Codes
83520<br><strong>This test is not available for New York patient testing.</strong>
Preferred Specimen
0.7 mL plasma collected in an EDTA (lavender-top) tube
Patient Preparation
Patients should be cautioned to stop biotin consumption at least 72 hours prior to collection of a sample
Minimum Volume
0.5 mL
Instructions
Draw blood in an EDTA (lavender-top) tube. Invert to mix with preservatives. Centrifuge and transfer plasma to a labeled plastic transport tube.
Transport Container
Transport tube
Transport Temperature
Room temperature
Specimen Stability
Room temperature: 43 days
Refrigerated: 43 days
Frozen: 40 days
Refrigerated: 43 days
Frozen: 40 days
Methodology
Electrochemiluminescence Immunoassay
Setup Schedule
Set up: Tues-Sat; Report available: 2-4 days
Reference Range
<20 years | Not Established |
20-39 years | <68.9 pg/mL |
40-49 years | <74.2 pg/mL |
50-59 years | <86.5 pg/mL |
≥60 years | <156.9 pg/mL |
Clinical Significance
Glial fibrillary acidic protein (GFAP) is a protein expressed in astrocytes, cells that support neurons and help form the blood-brain barrier, found within the central nervous system (CNS) and is involved in several important CNS processes. It is a marker of astrogliosis and is upregulated in the brain as a result of attempts at repair and the formation of a glial scar. Glial scarring occurs as a result of several neurodegenerative processes, including Alzheimer's disease, multiple sclerosis, and neuromyelitis optica. It can also be seen after damaging pathological events such as traumatic brain injury and stroke [1]. Increased presence of GFAP can also be observed in association with brain tumors such as glioblastoma multiforme [2]. GFAP expression is known to decrease in disorders such as schizophrenia, bipolar disorder, and depression [3].
1. Nature Reviews Neurology 18(3):158-172.
2. J Neuro Sci 35 (1):147-155.
3. Molecular Psychiatry 5(2):142-149.
1. Nature Reviews Neurology 18(3):158-172.
2. J Neuro Sci 35 (1):147-155.
3. Molecular Psychiatry 5(2):142-149.